Fig. 1From: Response to olaparib in metastatic castration-resistant prostate cancer with germline BRCA2 mutation: a case reportClinical course of the patient. Serum TPSA level was measured for disease monitoring. The timeline and duration of different treatments were indicated, as well as the time points for genetic testingBack to article page